A carregar...
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China
BACKGROUND: Our objective is to compare the cost-utility of icotinib and gefitinib for the second-line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. METHODS: Model technology was applied to assess the data of randomized clinical trial...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4807816/ https://ncbi.nlm.nih.gov/pubmed/27015267 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0151846 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|